Q-omics provides the consensus-scored KMT5AP2 profile across patient tissues and cancer cell-line models. KMT5AP2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KMT5AP2 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, KMT5AP2 RNA expression shows 13,897 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where KMT5AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KMT5AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KMT5AP2 survival associations across molecular data types. KMT5AP2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KMT5AP2 RNA expression–survival associations across cancer types. High KMT5AP2 expression shows unfavorable associations in LUAD, LGG, KIRP, ACC and SKCM, but favorable associations in READ. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KMT5AP2 RNA expression.
This table summarizes KMT5AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KMT5AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KMT5AP2 shows lower tumor expression in THCA, KICH, KIRC and PAAD and higher tumor expression in CHOL and LUSC. The THCA box plot shows higher KMT5AP2 RNA expression in normal versus tumor tissue (log2 FC = −0.086, t-test p < 0.001).
This table shows molecular features associated with KMT5AP2 in patient tissues and cancer cell lines. In patient samples, KMT5AP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
